Delving into the Latest Updates on OLP-210 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

OLP-210

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Obesity

Inactive Indication-

Originator Organization

Shenzhen Aoli Biotechnology Co., Ltd.

Active Organization

Shenzhen Aoli Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

1)评价OLP-210片在健康受试者中单次给药的安全性、药代动力学特征和免疫原性。 2)比较在健康受试者中单次给予OLP-210片与司美格鲁肽注射液（诺和盈®）后的药代动力学特征。 3)评价OLP-210片在肥胖和超重患者中多次给药的安全性、药代动力学、药效动力学特征和免疫原性。 4)比较在肥胖和超重患者中多次给予OLP-210片与司美格鲁肽注射液（诺和盈®）后的药代动力学、药效动力学特征。

[Translation]

1) Evaluate the safety, pharmacokinetic characteristics and immunogenicity of single-dose OLP-210 tablets in healthy subjects. 2) Compare the pharmacokinetic characteristics of single-dose OLP-210 tablets and semaglutide injection (Novowin®) in healthy subjects. 3) Evaluate the safety, pharmacokinetics, pharmacodynamic characteristics and immunogenicity of multiple-dose OLP-210 tablets in obese and overweight patients. 4) Compare the pharmacokinetic and pharmacodynamic characteristics of multiple-dose OLP-210 tablets and semaglutide injection (Novowin®) in obese and overweight patients.

Start Date-

Sponsor / Collaborator

Shenzhen Aoli Biotechnology Co., Ltd.

100 Clinical Results associated with OLP-210

Login to view more data

100 Translational Medicine associated with OLP-210

Login to view more data

100 Patents (Medical) associated with OLP-210

Login to view more data

100 Deals associated with OLP-210

Login to view more data